Compare RM & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RM | TTRX |
|---|---|---|
| Founded | 1987 | 2015 |
| Country | United States | United States |
| Employees | N/A | 2 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 334.1M | 281.2M |
| IPO Year | 2011 | N/A |
| Metric | RM | TTRX |
|---|---|---|
| Price | $41.65 | $8.54 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $30.00 | $8.00 |
| AVG Volume (30 Days) | 70.6K | ★ 124.9K |
| Earning Date | 04-29-2026 | 05-31-2026 |
| Dividend Yield | ★ 3.12% | N/A |
| EPS Growth | ★ 7.49 | N/A |
| EPS | ★ 1.18 | N/A |
| Revenue | ★ $645,598,000.00 | N/A |
| Revenue This Year | $12.94 | N/A |
| Revenue Next Year | $8.97 | N/A |
| P/E Ratio | $34.84 | ★ N/A |
| Revenue Growth | ★ 9.70 | N/A |
| 52 Week Low | $30.46 | $2.57 |
| 52 Week High | $46.00 | $11.69 |
| Indicator | RM | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 55.26 | 55.17 |
| Support Level | $35.76 | $8.51 |
| Resistance Level | $44.30 | $11.69 |
| Average True Range (ATR) | 1.60 | 1.12 |
| MACD | -0.28 | -0.10 |
| Stochastic Oscillator | 45.33 | 27.11 |
Regional Management Corp is a diversified consumer finance company that provides installment loan products to customers with limited access to consumer credit from banks, thrifts, credit card companies, and other lenders. The company is engaged in consumer finance. The company has the core products which are small and large installment loans. The company also offers optional payment and collateral protection insurance. The company's principal source of revenue is interest and fee income on outstanding loans.
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.